Trial registration number
|
JPRN-jRCTs031210370 |
Full text link
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
https://jrct.niph.go.jp/latest-detail/jRCTs031210370
|
First author
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Hiroko Kumashiro
|
Contact
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
hiroko-kumashiro@lta-med.com
|
Registration date
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
2021-10-08
|
Recruitment status
Last imported at : March 4, 2022, 2 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Not recruiting
|
Study design
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
RCT
|
Allocation
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Randomized
|
Design
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Parallel
|
Masking
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Blind label
|
Center
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
unclear
|
Study aim
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Prevention
|
Inclusion criteria
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1. Those who have provided the documented informed consent to participate in the research2. Male / female adults aged 20 or older
|
Exclusion criteria
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1. Those who clearly have a serious acute disease2. Those who have a history of severe hypersensitivity to ingredients in the investigational product3. Those who receive anticoagulation treatment or have thromboembolism, thrombocytopenia or clotting disorder4. Those who have previously diagnosed with immunodeficiency or have any close relatives with congenital immunodeficiency5. Those who have underlying disease such as cardiovascular disease, renal disease, hepatic disease, hematologic disease or developmental disability6. Those who have been vaccinated with the investigational product7. Those who have a history of capillary leak syndrome8. Those who have been vaccinated with non-investigational product in 14 days prior to investigational product 9. Those who have received immunosuppressant (except for topical steroid, and low dose steroid used for less than 14 days) in 6 months prior to investigational product10. Those who are considered inappropriate for the research at PI's (or SI's) discretion other than the above
|
Number of arms
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1
|
Funding
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Tsuru Tomomi
|
Inclusion age min
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
20
|
Inclusion age max
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
100
|
Countries
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Japan
|
Type of patients
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Healthy volunteers
|
Severity scale
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
N/A
|
Total sample size
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
270
|
primary outcome
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1. Safety:-Adverse Events-Assessment items in electronic health assessment diary2. Antibody durability and Immunogenicity-SARS-CoV-2 serum neutralizing antibody-SARS-CoV-2 S binding antibody-SARS-CoV-2 N binding antibody-Cell-mediated immunity assessment (Confirming whether or not there are antigen-specific T cells / antigen-specific B cells)
|
Notes
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
|
Phase
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Not reported
|
Arms
Last imported at : Jan. 13, 2022, 11 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
[{"arm_notes": "2nd dose;Against the three variant strains of COVID-19; each combination of the same vaccines and different vaccines is to be dosed twice with 4-week interval. The combination makes 9 arms in the trial.", "treatment_id": 1911, "treatment_name": "Covid-19 vaccine", "treatment_type": "Other covid vaccine", "pharmacological_treatment": "Vaccine"}]
|